Treatment of X-Linked Hypophosphatemia in Children
Abstract
:1. Introduction
2. Conventional Therapy
3. Possible Complications under Conventional Therapy
4. Clinical Trials of Burosumab
5. Safety of Burosumab
6. Indications for Burosumab Treatment in Children
7. Future Prospects for Burosumab Treatment
8. Summary
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Haffner, D.; Emma, F.; Eastwood, D.M.; Duplan, M.B.; Bacchetta, J.; Schnabel, D.; Wicart, P.; Bockenhauer, D.; Santos, F.; Levtchenko, E.; et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat. Rev. Nephrol. 2019, 15, 435–455. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Trombetti, A.; Al-Daghri, N.; Brandi, M.L.; Cannata-Andía, J.B.; Cavalier, E.; Chandran, M.; Chaussain, C.; Cipullo, L.; Cooper, C.; Haffner, D.; et al. Interdisciplinary management of FGF23-related phosphate wasting syndromes: A Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia. Nat. Rev. Endocrinol. 2022, 18, 366–384. [Google Scholar] [CrossRef] [PubMed]
- Takashi, Y.; Kawanami, D.; Fukumoto, S. FGF23 and Hypophosphatemic Rickets/Osteomalacia. Curr. Osteoporos. Rep. 2021, 19, 669–675. [Google Scholar] [CrossRef] [PubMed]
- Michigami, T. Advances in understanding of phosphate homeostasis and related disorders. Endocr. J. 2022, EJ22-0239. [Google Scholar] [CrossRef] [PubMed]
- Glorieux, F.H.; Marie, P.J.; Pettifor, J.M.; Delvin, E.E. Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets. N. Engl. J. Med. 1980, 303, 1023–1031. [Google Scholar] [CrossRef]
- Petersen, D.J.; Boniface, A.M.; Schranck, F.W.; Rupich, R.C.; Whyte, M.P. X-linked hypophosphatemic rickets: A study (with literature review) of linear growth response to calcitriol and phosphate therapy. J. Bone Miner. Res. 1992, 7, 583–597. [Google Scholar] [CrossRef]
- Carpenter, T.O.; Imel, E.A.; Holm, I.A.; De Beur, S.M.J.; Insogna, K.L. A clinician’s guide to X-linked hypophosphatemia. J. Bone Miner. Res. 2011, 26, 1381–1388. [Google Scholar] [CrossRef] [Green Version]
- Linglart, A.; Duplan, M.B.; Briot, K.; Chaussain, C.; Esterle, L.; Guillaume-Czitrom, S.; Kamenicky, P.; Nevoux, J.; Prié, D.; Rothenbuhler, A.; et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr. Connect. 2014, 3, R13–R30. [Google Scholar] [CrossRef] [PubMed]
- Rafaelsen, S.; Johansson, S.; Ræder, H.; Bjerknes, R. Hereditary hypophosphatemia in Norway: A retrospective population-based study of genotypes, phenotypes, and treatment complications. Eur. J. Endocrinol. 2016, 174, 125–136. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mäkitie, O.; Doria, A.; Kooh, S.W.; Cole, W.G.; Daneman, A.; Sochett, E. Early Treatment Improves Growth and Biochemical and Radiographic Outcome in X-Linked Hypophosphatemic Rickets. J. Clin. Endocrinol. Metab. 2003, 88, 3591–3597. [Google Scholar]
- Yamazaki, Y.; Tamada, T.; Kasai, N.; Urakawa, I.; Aono, Y.; Hasegawa, H.; Fujita, T.; Kuroki, R.; Yamashita, T.; Fukumoto, S.; et al. Anti-FGF23 Neutralizing Antibodies Show the Physiological Role and Structural Features of FGF23. J. Bone Miner. Res. 2008, 23, 1509–1518. [Google Scholar] [CrossRef] [PubMed]
- Aono, Y.; Yamazaki, Y.; Yasutake, J.; Kawata, T.; Hasegawa, H.; Urakawa, I.; Fujita, T.; Wada, M.; Yamashita, T.; Fukumoto, S.; et al. Therapeutic Effects of Anti-FGF23 Antibodies in Hypophosphatemic Rickets/Osteomalacia. J. Bone Miner. Res. 2009, 24, 1879–1888. [Google Scholar] [CrossRef] [PubMed]
- Carpenter, T.O.; Whyte, M.P.; Imel, E.A.; Boot, A.M.; Högler, W.; Linglart, A.; Padidela, R.; Van’t Hoff, W.; Mao, M.; Chen, C.Y.; et al. Burosumab therapy in children with X-linked hypophosphatemia. N. Engl. J. Med. 2018, 378, 1987–1998. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Whyte, M.P.; Carpenter, T.O.; Gottesman, G.S.; Mao, M.; Skrinar, A.; Martin, J.S.; Imel, E.A. Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: A multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol. 2019, 7, 189–199. [Google Scholar] [CrossRef]
- Imel, E.A.; Glorieux, F.H.; Whyte, M.P.; Munns, C.F.; Ward, L.M.; Nilsson, O.; Simmons, J.H.; Padidela, R.; Namba, N.; Cheong, H.I.; et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: A randomised, active-controlled, open-label, phase 3 trial. Lancet 2019, 393, 2416–2427. [Google Scholar] [CrossRef]
- Linglart, A.; Imel, E.A.; Whyte, M.P.; Portale, A.A.; Högler, W.; Boot, A.M.; Padidela, R.; Van’t Hoff, W.; Gottesman, G.S.; Chen, A.; et al. Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia. J. Clin. Endocrinol. Metab. 2022, 107, 813–824. [Google Scholar] [CrossRef] [PubMed]
- Namba, N.; Kubota, T.; Muroya, K.; Tanaka, H.; Kanematsu, M.; Kojima, M.; Orihara, S.; Kanda, H.; Seino, Y.; Ozono, K. Safety and Efficacy of Burosumab in Pediatric Patients With X-linked Hypophosphatemia: A Phase 3/4 Open-Label Trial. J. Endocr. Soc. 2022, 6, bvac021. [Google Scholar] [CrossRef]
- Harrell, R.M.; Lyles, K.W.; Harrelson, J.M.; Friedman, N.E.; Drezner, M.K. Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol. J. Clin. Investig. 1985, 75, 1858–1868. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Miyamoto, J.; Koto, S.; Hasegawa, Y. Final Height of Japanese Patients with X-Linked Hypophosphatemic Rickets Effect of Vitamin D and Phosphate Therapy. Endocr. J. 2000, 47, 163–167. [Google Scholar] [CrossRef] [Green Version]
- Heude, B.; Scherdel, P.; Werner, A.; Le Guern, M.; Gelbert, N.; Walther, D.; Arnould, M.; Bellaïche, M.; Chevallier, B.; Cheymol, J.; et al. A big-data approach to producing descriptive anthropometric references: A feasibility and validation study of paediatric growth charts. Lancet Digit. Health 2019, 1, e413–e423. [Google Scholar] [CrossRef] [Green Version]
- Sochett, E.; Doria, A.S.; Henriques, F.; Kooh, S.W.; Daneman, A.; Mäkitie, O. Growth and Metabolic Control during Puberty in Girls with X-Linked Hypophosphataemic Rickets. Horm. Res. Paediatr. 2004, 61, 252–256. [Google Scholar] [CrossRef] [PubMed]
- Ariceta, G.; Langman, C.B. Growth in X-linked hypophosphatemic rickets. Eur. J. Pediatr. 2006, 166, 303–309. [Google Scholar] [CrossRef] [PubMed]
- Zivicnjak, M.; Schnabel, D.; Billing, H.; Staude, H.; Filler, G.; Querfeld, U.; Schumacher, M.; Pyper, A.; Schroder, C.; Bramswig, J.; et al. Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets. Pediatr. Nephrol. 2011, 26, 2231–2232. [Google Scholar] [CrossRef] [PubMed]
- Quinlan, C.; Guegan, K.; Offiah, A.; Neill, R.O.; Hiorns, M.P.; Ellard, S.; Bockenhauer, D.; Hoff, W.V.; Waters, A.M. Growth in PHEX-associated X-linked hypophosphatemic rickets: The importance of early treatment. Pediatr. Nephrol. 2012, 27, 581–588. [Google Scholar] [CrossRef]
- Santos, F.; Fuente, R.; Mejia, N.; Mantecon, L.; Gil-Peña, H.; Ordoñez, F.A. Hypophosphatemia and growth. Pediatr. Nephrol. 2013, 28, 595–603. [Google Scholar] [CrossRef]
- Mao, M.; Carpenter, T.O.; Whyte, M.P.; Skrinar, A.; Chen, C.-Y.; Martin, J.S.; Rogol, A.D. Growth Curves for Children with X-linked Hypophosphatemia. J. Clin. Endocrinol. Metab. 2020, 105, 3243–3249. [Google Scholar] [CrossRef]
- Cheung, M.; Roschger, P.; Klaushofer, K.; Veilleux, L.-N.; Roughley, P.; Glorieux, F.H.; Rauch, F. Cortical and Trabecular Bone Density in X-Linked Hypophosphatemic Rickets. J. Clin. Endocrinol. Metab. 2013, 98, E954–E961. [Google Scholar] [CrossRef] [Green Version]
- Colares Neto, G.P.; Pereira, R.M.R.; Alvarenga, J.C.; Takayama, L.; Funari, M.F.A.; Martin, R.M. Evaluation of bone mineral density and microarchitectural parameters by DXA and HR-pQCT in 37 children and adults with X-linked hypophosphatemic rickets. Osteoporos. Int. 2017, 28, 1685–1692. [Google Scholar] [CrossRef]
- Cauliez, A.; Zhukouskaya, V.V.; Hilliquin, S.; Sadoine, J.; Slimani, L.; Miceli-Richard, C.; Briot, K.; Linglart, A.; Chaussain, C.; Bardet, C. Impact of Early Conventional Treatment on Adult Bone and Joints in a Murine Model of X-Linked Hypophosphatemia. Front. Cell Dev. Biol. 2021, 8, 591417. [Google Scholar] [CrossRef]
- Miao, D.; Bai, X.; Panda, D.K.; Karaplis, A.C.; Goltzman, D.; McKee, M.D. Cartilage abnormalities are associated with abnormal Phex expression and with altered matrix protein and MMP-9 localization in Hyp mice. Bone 2004, 34, 638–647. [Google Scholar] [CrossRef]
- Fuente, R.; García-Bengoa, M.; Fernández-Iglesias, Á.; Gil-Peña, H.; Santos, F.; López, J.M. Cellular and Molecular Alterations Underlying Abnormal Bone Growth in X-Linked Hypophosphatemia. Int. J. Mol. Sci. 2022, 23, 934. [Google Scholar] [CrossRef] [PubMed]
- Alon, U.S.; Lovell, H.B.; Donaldson, D.L. Nephrocalcinosis, hyperparathyroidism, and renal failure in familial hypophosphatemic rickets. Clin. Pediatr. 1992, 31, 180–183. [Google Scholar] [CrossRef] [PubMed]
- Latta, K.; Hisano, S.; Chan, J.C.M. Therapeutics of X-linked hypophosphatemic rickets. Pediatr. Nephrol. 1993, 7, 744–748. [Google Scholar] [CrossRef] [PubMed]
- DeLacey, S.; Liu, Z.; Broyles, A.; El-Azab, S.A.; Guandique, C.F.; James, B.C.; Imel, E.A. Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients. Bone 2019, 127, 386–392. [Google Scholar] [CrossRef]
- Lecoq, A.-L.; Chaumet-Riffaud, P.; Blanchard, A.; Dupeux, M.; Rothenbuhler, A.; Lambert, B.; Durand, E.; Boros, E.; Briot, K.; Silve, C.; et al. Hyperparathyroidism in Patients With X-Linked Hypophosphatemia. J. Bone Miner. Res. 2020, 35, 1263–1273. [Google Scholar] [CrossRef]
- Alon, U.S.; Monzavi, R.; Lilien, M.; Rasoulpour, M.; Geffner, M.E.; Yadin, O. Hypertension in hypophosphatemic rickets—Role of secondary hyperparathyroidism. Pediatr. Nephrol. 2003, 18, 155–158. [Google Scholar] [CrossRef]
- Nakamura, Y.; Takagi, M.; Takeda, R.; Miyai, K.; Hasegawa, Y. Hypertension is a characteristic complication of X-linked hypophosphatemia. Endocr. J. 2017, 64, 283–289. [Google Scholar] [CrossRef] [Green Version]
- Zhang, X.; Imel, E.; Ruppe, M.D.; Weber, T.J.; Klausner, M.A.; Ito, T.; Vergeire, M.; Humphrey, J.; Glorieux, F.H.; Portale, A.A.; et al. Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia. J. Clin. Pharmacol. 2016, 56, 176–185. [Google Scholar] [CrossRef] [Green Version]
- Zhang, X.; Peyret, T.; Gosselin, N.H.; Marier, J.F.; Imel, E.A.; Carpenter, T.O. Population pharmacokinetic and pharmacodynamic analyses from a 4-month intradose escalation and its subsequent 12-month dose titration studies for a human monoclonal anti-FGF23 antibody (KRN23) in adults with X-linked hypophosphatemia. J. Clin. Pharmacol. 2016, 56, 429–438. [Google Scholar] [CrossRef]
- Thacher, T.; Pettifor, J.; Tebben, P.J.; Creo, A.L.; Skrinar, A.; Mao, M.; Chen, C.-Y.; Chang, T.; Martin, J.S.; Carpenter, T.O. Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: Utility of the radiographic Rickets Severity Score. Bone 2019, 122, 76–81. [Google Scholar] [CrossRef]
- Whyte, M.P.; Fujita, K.P.; Moseley, S.; Thompson, D.D.; McAlister, W.H. Validation of a Novel Scoring System for Changes in Skeletal Manifestations of Hypophosphatasia in Newborns, Infants, and Children: The Radiographic Global Impression of Change Scale. J. Bone Miner. Res. 2018, 33, 868–874. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Imel, E.A. Burosumab for Pediatric X-Linked Hypophosphatemia. Curr. Osteoporos. Rep. 2021, 19, 271–277. [Google Scholar] [CrossRef] [PubMed]
Dose (Ref. [2]) | Number of Doses per Day | |
---|---|---|
Phosphorus | 20–60 mg/kg/day (initial dose) | 4–6 times/day |
Alfacalcidol Calcitriol | 0.03–0.05 mg/kg/day 0.02–0.03 mg/kg/day | Once a day One or two doses |
Ref [13] | Ref [14] | Ref [15] | Ref [16] 1 | Ref [17] | |
---|---|---|---|---|---|
Number of patients (age) | 52 (5–12 years) | 13 (1–4 year) | 61 (1–12 years) | 52 (5–12 years) | 15 (1–12 years) |
Burosumab dose | N = 26 Q2W 2 (initial 0.1 mg/kg, titrated to mean 0.98 mg/kg) N = 26 Q4W 3 (initial 0.2 mg/kg, titrated mean 1.5 mg/kg) | 0.8–1.2 mg/kg Q2W | N = 29 Burosumab 0.8–1.2 mg/kg Q2W N = 32 Conventional therapy | 0.8–1.2 mg/kg Q2W | 0.8–1.2 mg/kg Q2W |
Change of RSS Mean ± SD | At base line Q2W 1.9 ± 1.2 Q4W 1.7 ± 1.0 At 64 weeks Q2W 0.8 ± 0.6 Q4W 0.9 ± 0.5 | At base line 2.9 ± 1.2 At 64 weeks 0.9 ± 0.5 4 | At base line Burosumab 3.2 ± 1.1 Conventional therapy 3.2 ± 1.0 At 64 weeks Burosumab 1.0 ± 0.7 4 Conventional therapy 2.2 ± 0.8 4 | At 160 weeks RSS decreased in 41/52 patients | At base line 1.3 ± 1.2 |
Change of RGC-I LSM 5 ± SE | Q2W 0.8 ± 0.6 at 64 weeks Q4W 0.9 ± 0.5 at 64 weeks | 0.9 ± 0.5 (RGI-C score ≧+2 13/13) patients) 6 | Burosumab at 64 weeks 1.0 ± 0.7 4 (RGI-C score ≧+2 25/29 patients) 6 Conventional at 64 weeks 2.2 ± 0.8 4 (RGI-C score ≧+2 6/32 patients) | LSM (SE) from base line to week 160 +1.89 ± 0.1 (RGI-C score ≧+2 23/41 patients at 160 weeks) 6 | Global RGC-I At 40 weeks 1.5 ± 0.8 At the end of treatment (average 121.7 weeks) 2.1 ± 0.7 |
Effect on length of height change after burosumab | Mean change of height Z score Q2W +0.19 at 64 weeks Q4W +0.12 at 64 weeks | Mean (SD) recumbent length or standing height Z score −1.38 ± 1.1 at base line −1.64 ± 1.09 at 63 weeks | LSM (SE) at 64 weeks Burosumab 0.17 ± 0.07 Conventional therapy 0.02 ± 0.04 | Mean (SD) height Z score Q4W→Q2W −2.05 ± 0.96 at base line −1.85 ± 0.85 at 160 weeks Q2W→Q2W −1.72 ± 1.03 at base line −1.38 ± 1.06 at 160 weeks | No change of height Z score from baseline |
|
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tajima, T.; Hasegawa, Y. Treatment of X-Linked Hypophosphatemia in Children. Endocrines 2022, 3, 522-529. https://doi.org/10.3390/endocrines3030042
Tajima T, Hasegawa Y. Treatment of X-Linked Hypophosphatemia in Children. Endocrines. 2022; 3(3):522-529. https://doi.org/10.3390/endocrines3030042
Chicago/Turabian StyleTajima, Toshihiro, and Yukihiro Hasegawa. 2022. "Treatment of X-Linked Hypophosphatemia in Children" Endocrines 3, no. 3: 522-529. https://doi.org/10.3390/endocrines3030042